




The relative strengths and weaknesses of Dianthus Therapeutics Inc DE are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Dianthus Therapeutics Inc DE compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 129% points. The greatest weakness of Dianthus Therapeutics Inc DE is the variable Research and Development, reducing the Economic Capital Ratio by 16% points.

The company's Economic Capital Ratio, given in the ranking table, is 338%, being 100% points above the market average of 238%.

Input Variable	Value in 1000 USD
Assets, Current	149,843
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	14,115
Liabilities, Non-Current	0
Other Assets	1,780
Other Compr. Net Income	16
Other Expenses	0
Other Liabilities	6,206
Other Net Income	0
Other Revenues	6,200
Property and Equipment	9,891
Research and Development	59,208
Selling, General and Administrative Expense	23,761

Output Variable	Value in 1000 USD
Assets	161,514
Liabilities	20,321
Expenses	82,969
Revenues	6,200
Stockholders Equity	141,193
Net Income	-76,769
Comprehensive Net Income	-76,761
BaseVar	135,510
ECR before Limited Liability	254%
Economic Capital Ratio	338%